Device and method for treating ophthalmic diseases
First Claim
Patent Images
1. A method for delivering a biologically active molecule to the eye comprising:
- implanting a capsule periocularly in the sub-Tenon'"'"'s space, the capsule comprising a core containing a cellular source of the biologically active molecule and a surrounding biocompatible jacket, the jacket permitting diffusion of the biologically active molecule into the eye wherein the dosage of the biologically active molecule delivered is between 50 pg and 1000 ng per eye per patient per day.
8 Assignments
0 Petitions
Accused Products
Abstract
A method and device for delivering a biologically active molecule to the eye, either intraocularly or periocularly, and method and device for treating ophthalmic disorders in a patient suffering therefrom.
-
Citations
50 Claims
-
1. A method for delivering a biologically active molecule to the eye comprising:
implanting a capsule periocularly in the sub-Tenon'"'"'s space, the capsule comprising a core containing a cellular source of the biologically active molecule and a surrounding biocompatible jacket, the jacket permitting diffusion of the biologically active molecule into the eye wherein the dosage of the biologically active molecule delivered is between 50 pg and 1000 ng per eye per patient per day. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
8. A method for delivering a biologically active molecule to the eye comprising:
implanting a capsule intraocularly, the capsule comprising a core containing a cellular source of the biologically active molecule and a surrounding biocompatible jacket, the jacket permitting diffusion of the biologically active molecule into the eye wherein the dosage of the biologically active molecule delivered is between 50 pg to 500 ng per eye per patient per day. - View Dependent Claims (9, 10, 11, 12, 13, 14)
-
15. A method for delivering a biologically active molecule to the eye comprising implanting a capsule intraocularly, the capsule comprising a core containing a cellular source of the biologically active molecule and a surrounding biocompatible jacket, the jacket permitting diffusion of the biologically active molecule into the eye wherein a second biologically active molecule or peptide is co-delivered from the capsule to the eye.
-
16. A method for delivery of biologically active molecules to an eye comprising:
-
implanting a first capsule intraocularly, the first capsule comprising a core containing a cellular source of a first biologically active molecule and a surrounding biocompatible jacket, the jacket permitting difffusion of the first biologically active molecule into the eye;
implanting a second capsule periocularly, the second capsule comprising a core containing a cellular source of a second biologically active molecule and a surrounding biocompatible, immunoisolatory jacket, the jacket permitting diffusion of the second biologically active molecule into the eye. - View Dependent Claims (17)
-
-
18. A method for treating ophthalmic disorders in a patient suffering therefrom, comprising:
-
implanting into an eye of the patient a biocompatible capsule, the capsule comprising (a) a core comprising a cellular source of a biologically active molecule, and (b) a jacket surrounding said core, the jacket comprising a biocompatible material that permits diffusion of the biologically active molecule to the eye in a therapeutically effective amount, wherein the dosage of the biologically active molecule that diffuses into the eye is between 50 pg and 1000 ng per eye per patient per day. - View Dependent Claims (19, 20, 21, 22, 23, 24)
-
-
25. A method for treating ophthalmic disorders in a patient suffering therefrom, comprising:
-
implanting into an eye a biocompatible capsule, the capsule comprising;
(a) a core comprising a cellular source of a biologically active molecule, and (b) a jacket surrounding said core, the jacket comprising a biocompatible material that permits diffusion of the biologically active molecule to the eye in a therapeutically effective amount, wherein a second biologically active molecule is co-delivered to the eye.
-
-
26. A device for delivery of a biologically active molecule to the eye comprising a capsule, the capsule comprising:
-
a core comprising encapsulated cells that produce a biologically active molecule, a biocompatible jacket surrounding said core, the jacket permitting diffusion of the biologically active molecule into the eye, the capsule configured as a hollow fiber, with an outer diameter of less than or equal to 1 mm, and a length between 0.4 and 1.5 cm, wherein the dosage of the biologically active molecule that diffuses into the eye is between 50 pg and 1000 ng per eye per patient per day. - View Dependent Claims (28)
-
-
27. A device for delivery of a biologically active molecule to the eye comprising a capsule, the capsule comprising:
-
a core comprising encapsulated cells that produce a biologically active molecule, a biocompatible jacket surrounding said core, the jacket permitting diffusion of the biologically active molecule into the eye, the capsule configured as a flat sheet having a surface area less than or equal to 25 mm2, wherein the dosage of the biologically active molecule that diffuses into the eye is between 50 pg and 1000 ng per eye per patient per day.
-
-
29. An encapsulated cell system for periocular delivery of a biologically active molecule to the eye comprising:
at least one capsule, each capsule comprising a core containing a cellular source of a biologically active molecule and a surrounding biocompatible jacket, the jacket permitting diffusion of the biologically active molecule into the eye, the encapsulated cell system delivering 50 pg to 1000 ng periocularly per eye per patient per day of the biologically active molecule. - View Dependent Claims (30, 31, 32, 33, 34, 36)
-
35. The system of claim w wherein the biologically active molecule is selected from the group consisting of anti-angiogenic factors, anti-inflammatory factors, neurotrophic factors, and combinations thereof.
-
37. An encapsulated cell system for periocular delivery of a biologically active molecule to the eye comprising:
at least one capsule, each capsule comprising a core containing a cellular source of a biologically active molecule and a surrounding biocompatible jacket, the jacket permitting diffusion of the biologically active molecule into the eye, the encapsulated cell system delivering 50 pg to 1000 ng periocularly per eye per patient per day of the biologically active molecule, wherein a second biologically active molecule or peptide is co-delivered from the capsule to the eye. - View Dependent Claims (38)
-
39. An encapsulated cell system for intraocular delivery of a biologically active molecule to the eye comprising:
at least one capsule, each capsule comprising a core containing a cellular source of a biologically active molecule and a surrounding biocompatible jacket, the jacket permitting diffusion of the biologically active molecule into the eye, the encapsulated cell system delivering 50 pg to 500 ng intraocularly per eye per patient per day of the biologically active molecule. - View Dependent Claims (40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)
Specification